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THERAPY 
Patients with deep vein thrombosis may be treated in 
three different ways: by surgical thrombectomy, medical 
lysis, or simple heparinization.1-3 Usually, a certain form 
of standardization is used for each of the three different 
therapies. Despite this fact, the question remains: which is 
the best form of therapy? 
In the literature, numerous studies dealing with the 
problem of the therapy of deep vein thrombosis can be 
found. A correct evaluation, however, appears extremely 
difficult because most studies were designed retrospec-
tively, mostly addressing only one form of therapy,3"5 and 
because results are hardly comparable, since no unique 
criteria for evaluation of the success of therapy were 
applied. Many investigators simply relied on the patients' 
subjective complaints. Others additionally took morpho-
logic criteria into consideration (mostly phlebographic 
results). Only a few considered functional parameters as 
important. Therefore, the aim of our study was, to evaluate 
the validity of each of the three therapies in a global 
concept. The study was designed prospectively using an 
ambitious protocol and considering the following three 
parameters: 
1. Clinical history and examination of the patient 
2. Morphologic status (such as phlebography) 
3. Functional status (such as phlebodynamometry) 
Patients and Methods 
Between January 2, 1984 and July 1, 1986, 233 deep 
vein thromboses in 209 patients were diagnosed phlebo-
graphically at the University of Munich, Klinikum Gross-
hadern. The form of therapy was determined inter-
disciplinarily. Thrombectomy was performed under 
general anesthesia with the preparation of the common 
femoral vein. For thrombectomy of the pelvic veins, a 
Fogarty catheter was used obligatorily. Leg veins were 
thrombectomized by compression.6 For lysis, streptoki-
nase (if contraindicated, urokinase) was used at standard 
dosages, that is, 250,000 IU as bolus within 30 minutes 
followed by 100,000 IU/hour by perfusor. Heparin therapy 
was administered by an initial injection of 10,000 IU, 
followed by continuous infusion using a perfusor and 
keeping the activated partial thromboplastin time between 
80 and 120 seconds. Additionally, all patients were treated 
with coumarin and compression stockings for 6 months. 
Sixty-eight (29%) patients were thrombectomized, 41 
(18%) were lysed, and 124 (53%) received heparin only 
(Fig. 1). 
Figure 2 shows two phlebodynamograms performed 
according to the method first described by Kriessmann.7'8 
The upper tracing is from a healthy patient, the lower one 
from a patient with post-thrombotic syndrome. 
Follow-up investigations were performed 8 days, 3 
and 6 months after start of therapy. Results were 
interpreted according to a clinical score listed in Table 1. 
In order to reduce the number of invasive procedures, the 
second follow-up investigation (after 3 months) was 
performed without a phlebography. 
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FIG. 2. Phlebodynamometry according to the method first 
described by Kriessmann in 1974. Puncture of a dorsal foot vein, 
intravenous pressure measurement by Statham. P1: hydro­
static basal pressure of patient at rest; P2: lowest mean pressure 
after ten toe standings within 15 seconds; P3: regained basal 
pressure after ten toe standings; AP: drop in pressure = P1 -P2; 
t1: time of drop in pressure; t2: time of pressure rebalance. 
TABLE 1. Score for Evaluation of the Success of 
Therapy of Deep Vein Thrombosis 
Excellent 
Good 
Fair 
Poor 
No complaints 
Phlebography: clear 
ΔP >50 mmHg 
No complaints 
Phlebography: some residual thrombi 
ΔP >50 mmHg 
Evening discomfort 
Phlebography: impaired drainage 
ΔP = 35 - 50 mmHg 
All day complaints 
Phlebography: impaired drainage 
ΔP <35 mmHg 
Results and Discussion 
The heterogeneity of the patient population can be 
seen from Figure 3 in which the age distribution for the 
three therapy groups is demonstrated. It is obvious that 
more elderly patients underwent heparin therapy than 
thrombectomy or lysis. This is due to the contraindications 
for the operative or lytic therapy, age itself being one (only 
exception is age greater than 65 years). Only 5.8 versus 
4.8% of all patients in the thrombectomy or lysis group, 
respectively, had malignant disease, whereas the cor­
responding number for the heparin treatment group was 
29.8%. Also the location of the thrombosis underscores 
the heterogeneity of the patient population (Fig. 4). 
Patients with pelvic vein thrombosis (mostly combined 
with thigh and lower leg thrombosis) were most com­
monly subjected to surgery. Patients with isolated lower 
leg thrombosis were most often treated with heparin. Lysis 
was favored in distal forms of venous thrombosis. The 
contraindications for operative and lytic therapy are listed 
in Table 2. The partly differing frequencies indicate the 
different judgments of the participants of the interdisci­
plinary study. In many patients, more than one contra­
indication was present (Table 3). Again, the large variety 
of contraindications and their different distribution under­
scores the divergence of the therapeutic groups. Of the 
large number of patients with contraindications for 
thrombectomy or lysis only 39 for patients with venous 
thromboses (16.7%) could have been treated with either 
thrombectomy or lysis (Fig. 5). Therefore a concurrence 
between these two therapies can hardly be stated. 
The value of the different forms of therapy of deep 
vein thrombosis can partly be elucidated from Figure 6, in 
which the results of the follow-up investigations 6 months 
after start of treatment are compiled. It is apparent that 
surgery and lysis yielded better results than heparin 
therapy alone. Still, in the heparin group, 22% demon­
strated excellent late results. Further analysis revealed that 
the patient population had exclusively partial lower leg 
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TABLE 2. Contraindications (Cl) for Surgery and Lysis and Their Encountered 
Frequency in 233 Vein Thromboses 
Surgery 
Location of thrombosis 
Age of thrombus 
Malignant disease 
Age of the patient 
Contraindications for anesthesia 
Pulmonary embolism 
% 
22 
21 
17 
16 
7 
5 
Lysis 
Previous operation 
Malignant disease 
Age of the patient 
Hypertension 
Age of thrombus 
Location of thrombosis 
Intramuscular puncture sites of trauma 
Central nervous system trauma or operation 
Gastric or duodenal ulcers 
Diabetes mellitus 
Hemorrhages 
Pregnancy 
Other 
% 
26 
18 
16 
13 
13 
11 
10 
7 
5 
4 
3 
3 
4 
vein thromboses. Apparently, the fibrinolysis mediated by 
the endothelium was sufficient for lysis of the relatively 
small masses of thrombi. 
The data shown in Figure 6 represent the largest 
patient population so far reinvestigated by the invasive and 
ambitious protocol. Nevertheless, the low absolute num-
ber of patients reinvestigated after 6 months limits the 
statements that can be made from our data. The main 
reason for the limited number of reinvestigations was a 
persistent immobilization, which made phlebody-
namometry impossible. Rarely, patients refused phlebog-
raphy. In the heparin group, 20% lethality was 
observed, almost exclusively as a result of malignant 
disease. When the results of the 39 venous thromboses 
without contraindications for surgery and lysis are com-
pared, both therapies show almost equally good results 
(Fig. 7). When excellent and good results are combined, 
the numbers are 53 and 58% for thrombectomy and lysis, 
respectively. Again, the exact interpretation of the results 
is restrained by the different locations of the thromboses 
in the different treatment groups. (In the surgical patients 
the combined pelvic, thigh, and lower leg vein thromboses 
were most frequently encountered). No good results with 
heparin alone were achieved in patients with combined 
FIG. 3. Age distribution of all patients with venous thromboses 
subdivided by form of therapy. 
FIG. 4. Frequency of location of thrombosis atthe pelvic, thigh, 
and lower leg level in percent of the total number of respective 
treatment group. 
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TABLE 3. Number of Contraindications for Surgery 
and Lysis 
No. 
Contraindications 
1 
2 
3 
4 
5 
Surgery 
(%) 
41 
18 
3 
0 
0 
Lysis 
(%) 
32 
24 
13 
2 
1 
pelvic, thigh, and lower leg vein thromboses when the 
process was 8 days or older before the onset of therapy. 
In comparison to the latter group of patients, with 55% 
excellent or good outcome, operative therapy gave the best 
results. With lysis comparable results were obtained in 
only 20% of the patients. Again, the low number of cases 
must be taken into consideration (Fig. 8). 
Conclusions 
A study comparing the results of different therapies 
of deep vein thrombosis has always to consider the 
heterogeneity of the patient population. The establishment 
of better comparable subgroups always results in a 
diminution of the total number of cases, hence limiting the 
reliability of the outcome. This is also applicable to this 
investigation. Nevertheless, the present data may be used 
as aids in the process of clinical decision-making. Heparin 
therapy is only indicated in an isolated thrombosis of the 
lower leg. In cases of combined thromboses in different 
compartments, lysis and surgery clearly reveal better 
results, but contraindications to thrombectomy and lysis 
must always be considered. In these patients therefore 
heparin treatment alone cannot be looked on as an 
adequate therapy. In combined pelvic, thigh, and lower leg 
thromboses, thrombectomy seems to be the most 
FIG. 5. Only 39 of the 233 incidences of deep vein thromboses 
could be treated either surgically or by lysis. 
FIG. 6. Results 6 months after therapy of deep vein thromb-
osis. Evaluation corresponding to the scores depicted in Table 
1 (33 operations, 20 lysis, 41 heparin). 
FIG. 7. Results 6 months after therapy of deep vein thromb-
osis. No contraindications for surgery and lysis (16 operation, 10 
lysis). 
FIG. 8. Results 6 months after onset of therapy in patients with 
combined pelvic, thigh, and lower leg thrombosis. Thrombus 
age less than 8 days. 
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promising form of treatment. Despite these guidelines for 
therapy of deep vein thrombosis, even with the aggressive 
forms of treatment (surgery and lysis), no completely 
satisfactory results can be obtained, still leaving a 40% 
incidence of postthrombotic syndrome. Thus, the question 
remains unanswered whether an additional approach 
might improve the present therapeutic possibilities. Our 
main interest has focused on platelets, which have so far 
been widely neglected from consideration in the venous 
system. This fact is difficult to understand, since thromb-
osis per se provokes endothelial damage, hence exposing 
an impaired vessel wall to the blood after successful 
treatment of thrombosis. Therefore, we studied in an 
animal experiment whether inhibition of platelet aggrega-
tion, already known to be effective for the arterial 
endothelium, also works on the venous vessel wall and, if 
so, whether this mechanism can be verified by endothelial 
damage. 
EXPERIMENTAL STUDY OF THE 
ANTITHROMBOGENICITY OF THE 
VENOUS WALL 
Among numerous complex metabolic functions, the 
normal vascular endothelium also demonstrates anti-
thrombotic properties by inhibiting coagulation,910 acti-
vating fibrinolysis,11 and inhibiting platelet aggregation 
(Fig. 9 a). From investigations with arterial endothelial 
cell cultures, it is known that endothelial cells contin-
uously secrete prostacyclin (PGI2) into the plasma, which 
inhibits platelet aggregation. This process is modified by 
numerous metabolic pathways, such as thrombin signif-
icantly increasing the release of PGI2.12,13 The endothelial 
cells can provide additional inhibition of platelet aggrega-
tion through a continuous secretion of adenosine into the 
plasma. Adenosine inhibits platelet aggregation in-
dependently from PGI2. In addition, the endothelial cells 
have a complete ectonucleotidase cascade, which rapidly 
degrades the accruing adenine nucleotides, adenosine 
triphosphate (ATP), adenosine diphosphate (ADP); both 
stimulating platelet aggregation, thereby accumulating the 
metabolite adenosine intraluminally.14,15 Such a release of 
ATP or ADP is the result of any cell moult and vessel wall 
trauma. Locally, concentrations as high as 10"2 M can be 
reached (Fig. 9 b). The aim of our investigation was to 
evaluate whether these metabolic pathways are of any 
importance in the venous endothelium and, if so, to what 
extent are they altered by thrombosis. Since these ques-
tions could not solely be addressed by investigations of 
endothelial cell cultures, an individual animal experiment 
was designed, allowing the study not only in an isolated 
perfused vessel, but also providing thrombosis experi-
ments in vivo. 
FIG. 9. a: Schematic representation of the endothelial properties 
preventing thrombosis, b: Schematic representation of physio-
logic, endothelium-mediated inhibition of platelet18 aggrega-
tion. (Modified according to Gerlach et al). 
Materials and Methods 
Isolated vena cava segments of rabbits were used for 
our experiments. The animals were anesthetized by 
ketamine and xylazine. In order to simulate the endothelial 
damage caused by thrombosis, before explantation, 
thrombin was applied by a catheter transfemorally to the 
infrarenally clamped vena cava. The resulting thrombus 
was conserved by an additional distal clamp. Some of the 
thrombosed segments were thrombectomized after 1 hour; 
for chronic thrombosis, the thrombus was fixed by 
ligations for 8 days and thrombectomized by a Fogarty 
catheter. After explantation, isolated vena cava segments 
were perfused under standardized conditions, with mod-
ified Earle's salt solution and HEPES buffer (Fig. 10). For 
investigations of reendothelialization, explantation was 
performed in some animals 14 days after thrombectomy of 
an 8-day-old thrombus. 
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FIG. 10. Isolated perfused vena cava segment, a: perfusion 
medium; b: external medium. 
After completion of the perfusion studies, vena cava 
segments were prepared for scanning electron micro-
scopy. Similarly, the structure of some thrombi was 
investigated.16 The activities of ectonucleotidases of the 
venous wall were determined by the metabolization of 
nucleotides (only shown for ADP) found in the perfusate 
(10-4 M). Measurements were performed by high- perfor-
mance liquid chromatography analysis.17 
Results 
Figures 11 to 13 show pictures of endothelium in 
different shapes, obtained by scanning electron micro-
scopy (SEM). Figure 11 depicts normal venous en-
dothelium after 8 hours of standardized perfusion, indicat-
ing no damage by the perfusion procedure itself. Figure 12 
clearly illustrates the luminal wall changes of chronically 
thrombosed veins ligated for 8 days. Drastic morphologic 
changes, such as completely deendothelialized venous 
wall segments, indicate the effect of longer lasting 
thrombosis on the vessel wall. Figure 13 shows a venous 
wall initially heavily damaged by a thrombus (8 days old) 
after 14 additional days of regeneration. The initial 
morphologic and physiologic changes (denudation of the 
vessel wall) have improved, the signs of proliferating cells 
are already visible, clearly indicating the regenerative 
capabilities of a previously damaged venous wall. Figure 
14 summarizes the results of our measurements of 
metabolites of nucleotides in isolated perfused vena cava 
segments with normal endothelium (a), after thrombosis 
for 1 hour and thrombectomy by irrigation without 
instrumental manipulation (b), and after thrombosis for 8 
days and thrombectomy by Fogarty catheter (c). As the 
figure indicates, compared with control experiments, 
thrombosed (for 1 hour) venous endothelium expectedly 
dephosphorylizes ADP rapidly. Adenosine production, 
however, is clearly decreased. This tendency to dimin-
ished adenosine accumulation during metabolism 
FIG. 11. Scanning electron microscopic picture of venous 
endothelium, after 8 hours of standardized perfusion. Intact 
endothelium is covering all of the subendothelial matrix. 
FIG. 12. Scanning electron microscopic picture of a vena cava 
segment after 8 days of thrombosis and thrombectomy. 
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FIG. 13. Scanning electron microscopic presentation of the 
intima of a vena cava segment after thrombosis for 8 days, 
thrombectomy, and 14 days of restitution. Among cell detritus, 
between proliferating endothelial cells (E), numerous wall-
adherent thrombocytes (T) are discernible. 
FIG. 14. Degradation of ADP (10-4M) in isolated perfused vena 
cava inferior segments of four rabbits (± SE). a: with intact 
endothelium (control); b: with thrombosis in situ (1 hour) and 
thrombectomy; c: with thrombosis in situ (8 days) and throm-
bectomy. 
of intraluminally applied ADP is drastically improved in 
the experiments with a thrombosis age of 8 days. Under 
such circumstances, adenosine hardly accumulates, re-
vealing inosine as the typical main degradation product. 
The changes in the intraluminal degradation of ADP 
could be due to different reasons and are not easily 
explained. In order to evaluate the extent of damage 
caused by the Fogarty catheter used for thrombectomy, the 
thrombus was also extracted by simple irrigation with PBS 
solution, excluding a direct instrumental trauma to the 
vessel well. The degradation of ADP revealed almost 
exactly the same results as depicted in Figure 14. This 
seems to suggest that the damage already caused by 
thrombosis alone is so extensive, that thrombectomy 
hardly causes a significant additional injury. 
The results of the nucleotide determination in reen-
dothelialized vena cava segments are shown in Figure 15. 
ADP is rapidly dephosphorylized. Interestingly, adeno-
sine monophosphate accumulated in the medium. Unlike 
the thrombosed and solely thrombectomized (without 
regeneration) veins, similar to the control vessels of 
untreated animals after reendothelialization of the venous 
segments, adenosine again represented the main fraction 
of dephosphorylized metabolites, again functionally sup-
porting the morphologic findings. 
FIG. 15. Degradation of ADP (10-4 M) in isolated perfused vena 
cava segments of rabbits, after thrombosis in situ (8 days), 
thrombectomy, and reendothelialization in situ (14 days). 
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Discussion 
Venous endothelium is provided with a complete 
ectonucleotidase cascade (Fig. 16 a), which rapidly 
degrades accrued adenine nucleotides to adenosine, inhib-
iting platelet aggregation. The degradation products 
inosine and hypoxanthine are inactive concerning platelet 
aggregation and emerge after cellular uptake of adenosine. 
If the integrity of the venous wall is damaged, liberation 
of adenosine desaminase takes place, rapidly degrading 
adenosine to inosine (result of special experiments, not 
shown). There is hardly any intermediate adenosine 
formed (Fig. 16 b). Hence, after venous endothelial 
damage, degradation of ATP or ADP by ectonucleotidases 
FIG. 16. a: Venous endothelium and its antiaggregatory prop-
erties: complete ectonucleotidase cascade. (Modified accord-
ing to Gerlach et al.18) b: Consequences of endothelial damage: 
platelet aggregation by degradation of adenosine. 
remains unchanged, compared with the intact vessel. By 
the lack of adenosine accumulation, the second possibility 
of effectively inhibiting platelet aggregation has vanished, 
thus causing a shift toward platelet aggregation. 
Conclusions 
Even by applying the most sophisticated modern 
possibilities of surgical procedures, a striking improve-
ment in the therapy of deep vein thrombosis can only be 
expected when our understanding of the pathogenesis 
improves, thus enabling the physician to look for more 
promising forms of therapy. In this context, it seems 
important to recognize, that not only surgical thrombect-
omy with a Fogarty catheter, but also thrombosis itself 
causes damage to the vessel wall favoring rethrombosis. 
In the experimental study, the venous endothelium could 
be proved to have a significant quantitative effect on the 
degradation of nucleotides favoring platelet aggregation. 
Chronic thrombosis already causes fundamental en-
dothelial damage. During reendothelialization, a normal-
ization of nucleotide metabolism can be observed. For the 
clinical practice, the following consequences can be 
summarized: 
1. Prophylaxis of thrombosis has to be performed aggres-
sively, preventing the origin of a deep vein thrombosis. 
2. In case of deep vein thrombosis, lysis offers an 
endothelium-saving procedure in fresh venous throm-
boses; in case of contraindications, thrombectomy may 
still be the method of choice. 
3. In case of older venous thrombosis, treated by lysis or 
operation, the reduction of antiaggregatory mecha-
nisms has to be considered. Future therapeutic efforts 
have to be directed toward additional antiaggregatory 
substances. 
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